tiprankstipranks
CUC Inc. (JP:9158)
:9158
Japanese Market
Want to see JP:9158 full AI Analyst Report?

CUC Inc. (9158) AI Stock Analysis

0 Followers

Top Page

JP:9158

CUC Inc.

(9158)

Select Model
Select Model
Select Model
Neutral 53 (OpenAI - 5.2)
Rating:53Neutral
Price Target:
¥746.00
▼(-12.03% Downside)
Action:Reiterated
Date:08/09/26
The score is primarily held back by financial quality concerns—persistently negative free cash flow, weak cash conversion, and rising leverage—despite improving revenue growth. Technicals further weigh on the score due to a clear downtrend and weak momentum. Valuation provides partial support with a low P/E, but it does not fully offset the cash flow and balance sheet risks.
Positive Factors
Revenue Growth
The renewed top-line acceleration indicates improving demand and business momentum. If sustained, stronger revenue growth can support operating scale, broaden the company’s care-facility platform, and help offset some margin and financing pressures.
Negative Factors
Negative Free Cash Flow
Persistent negative free cash flow indicates that reinvestment or working-capital needs are absorbing more cash than the business generates. Continued deficits could require external funding, constrain strategic flexibility, and increase dependence on debt.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The renewed top-line acceleration indicates improving demand and business momentum. If sustained, stronger revenue growth can support operating scale, broaden the company’s care-facility platform, and help offset some margin and financing pressures.
Read all positive factors

CUC Inc. (9158) vs. iShares MSCI Japan ETF (EWJ)

CUC Inc. Business Overview & Revenue Model

Company Description
CUC Inc. delivers a diverse range of healthcare provisions across Japan, throughout Asia, and globally. Their services cover critical areas like inpatient hospital care, specialized dialysis treatments, visiting nurse programs, and home hospice su...

CUC Inc. Financial Statement Overview

Summary
Improving revenue growth (9.9% in FY2026) and continued profitability are positives, but margin compression, rising leverage (debt-to-equity up to ~1.58), weak cash conversion (operating cash flow ~38% of net income), and three consecutive years of negative free cash flow materially increase financial risk.
Income Statement
67
Positive
Balance Sheet
56
Neutral
Cash Flow
38
Negative
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue55.52B54.35B47.04B33.02B35.21B35.31B
Gross Profit25.73B25.41B19.90B14.12B12.55B13.18B
EBITDA8.00B8.51B8.08B5.52B4.93B6.53B
Net Income2.36B2.85B3.13B2.60B2.42B2.71B
Balance Sheet
Total Assets101.14B98.05B85.17B62.84B39.75B34.53B
Cash, Cash Equivalents and Short-Term Investments18.33B15.84B7.53B8.26B4.12B4.36B
Total Debt56.69B52.53B43.54B26.72B21.45B14.90B
Total Liabilities67.32B64.16B54.88B34.83B27.83B24.85B
Stockholders Equity33.43B33.25B29.68B27.32B11.70B9.46B
Cash Flow
Free Cash Flow0.00-912.00M-3.04B-703.00M-3.10B5.79B
Operating Cash Flow0.005.71B2.50B4.16B2.36B6.62B
Investing Cash Flow0.00-3.38B4.45B-14.75B-6.68B-1.47B
Financing Cash Flow0.005.92B-7.60B14.37B3.97B-4.43B

CUC Inc. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price848.00
Price Trends
50DMA
770.00
Negative
100DMA
807.11
Negative
200DMA
858.00
Negative
Market Momentum
MACD
-5.75
Negative
RSI
53.54
Neutral
STOCH
76.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9158, the sentiment is Neutral. The current price of 848 is above the 20-day moving average (MA) of 737.80, above the 50-day MA of 770.00, and below the 200-day MA of 858.00, indicating a neutral trend. The MACD of -5.75 indicates Negative momentum. The RSI at 53.54 is Neutral, neither overbought nor oversold. The STOCH value of 76.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:9158.

CUC Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
¥46.08B11.413.04%5.16%37.79%
64
Neutral
¥2.35B4.863.83%2.01%2.55%
58
Neutral
¥5.64B11.680.40%13.29%17.57%
53
Neutral
¥22.22B9.4012.29%-0.34%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
49
Neutral
¥5.53B52.764.14%4.85%-85.27%
46
Neutral
¥4.05B12.225.24%14.91%-39.00%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:9158
CUC Inc.
758.00
-472.00
-38.37%
JP:2373
Care Twentyone Corporation
411.00
4.79
1.18%
JP:2435
Cedar. Co.,Ltd
209.00
-11.03
-5.01%
JP:6062
Charm Care Corporation
1,413.00
398.91
39.34%
JP:7061
Japan Hospice Holdings Inc.
477.00
-812.75
-63.02%
JP:7091
Living Platform Ltd.
1,257.00
314.97
33.44%

CUC Inc. Corporate Events

CUC Inc. Posts Revenue Growth but Swings to Quarterly Loss
Jul 30, 2026
CUC Inc., listed on the Tokyo Stock Exchange, operates in the services sector with a focus reflected in recurring revenue-generating operations across Japan. The company reports under IFRS and targets steady top-line growth while managing profitab...
CUC Details Governance Safeguards Under M3’s Majority Control
Jun 25, 2026
CUC Inc. disclosed details of its relationship with controlling shareholder M3, Inc., which holds 63.46% of CUC’s voting rights and positions the company within M3’s Site Solution segment serving healthcare professionals worldwide. The...
CUC Inc. Corrects Select Figures in FY2026 Consolidated Results
Jun 4, 2026
CUC Inc., a Tokyo Stock Exchange Growth-listed company, has issued a correction to its previously announced consolidated financial results for the fiscal year ended March 31, 2026 under IFRS. While the firm does not detail its operating sector in ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 09, 2026